Compare IDEXX Laboratories, Inc. (IDXX) vs Nutrien Ltd (NTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Nutrien Ltd — how do they compare? IDEXX Laboratories, Inc. trades at $543.91 (market cap $43.58B), while Nutrien Ltd trades at $68.42 (market cap $32.14B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Nutrien Ltd pays a 3.29% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | NTR | |
|---|---|---|
Market Cap | $43.58B | $32.14B |
Sector | Health | Basic Materials |
52-Week High | $766.68 | $83.94 |
52-Week Low | $526.44 | $53.64 |
Enterprise Value | $44.48B | $45.31B |
Dividend Yield | — | 3.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories trades at $552.46, down 2.64% today, with neutral technical signals but strong fundamental performance. The company maintains robust profitability with 24.63% net margins and has beaten earnings expectations for three consecutive quarters. Recent news highlights AI integration in medical devices and upcoming Q2 2026 results on August 4, 2026. The stock shows consistent revenue growth from $3.4B in 2022 to $4.3B in 2025.
Outlook remains positive given earnings momentum and analyst consensus, though elevated valuation ratios (P/E 41.49) pose risks. Key catalysts include Q2 earnings release and continued AI adoption in veterinary diagnostics. Primary risks involve competitive pressures and market volatility affecting premium valuations.
Nutrien (NTR) trades at $66.84, down 0.65% with neutral technical signals. The company shows improving fundamentals with Q1 2026 earnings beat and projected revenue growth to $27.8B in 2026. Valuation appears reasonable with P/E of 13.58 and P/S of 1.16. Recent institutional buying activity and a $0.55 dividend payment scheduled for July 2026 provide additional investor appeal.
The outlook remains positive with strong analyst consensus (60.6% buy ratings) and $77.67 price target suggesting 16% upside. Key risks include volatile input costs and fertilizer market dynamics. The combination of reasonable valuation, earnings momentum, and institutional support positions NTR favorably for long-term investors despite near-term market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
